Financial Performance - The company's Q3 2022 revenue reached ¥17,635.15 million, representing a year-over-year increase of 51.32%[5] - Net profit attributable to shareholders for Q3 2022 was ¥4,689.65 million, a decrease of 6.59% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,267.34 million, down 12.94% year-over-year[5] - Basic earnings per share for the first three quarters of 2022 were ¥0.5284, up 70.01% year-over-year[11] - The company reported a total revenue of ¥47,018.21 million for the first three quarters of 2022, reflecting a growth of 66.63% year-over-year[11] - The company achieved a net profit of ¥21,196.74 million for the first three quarters of 2022, an increase of 83.90% year-over-year[11] - The net profit attributable to shareholders for the first three quarters of 2022 was RMB 21,196.74 million, an increase of 83.90% compared to RMB 11,526.21 million in the same period of 2021[22] - The adjusted net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 14,532.64 million, up 32.72% from RMB 10,949.44 million year-on-year[22] - Total operating revenue for the first three quarters of 2022 reached ¥470,182,123.23, a significant increase from ¥282,163,223.04 in the same period of 2021, representing a growth of approximately 66.8%[31] - Net profit for the first three quarters of 2022 was ¥213,516,314.98, compared to ¥115,212,551.81 in 2021, reflecting an increase of approximately 85.5%[35] - The net profit attributable to the parent company shareholders for the first three quarters of 2022 was approximately CNY 211.97 million, compared to CNY 115.26 million in the same period of 2021, representing an increase of 83.8%[38] - The total comprehensive income attributable to the parent company owners for the first three quarters of 2022 was approximately CNY 212.92 million, up from CNY 115.22 million in the previous year, reflecting an increase of 84.8%[38] Research and Development - R&D expenses for Q3 2022 totaled ¥3,437.30 million, a significant increase of 120.41% year-over-year, reflecting the company's commitment to expanding its R&D team[8] - Research and development expenses amounted to ¥73,516,878.94, which is more than double the ¥35,386,011.09 spent in the previous year, showing a growth of about 108%[35] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥183,243.13 million, an increase of 43.21% compared to the end of the previous year[12] - The total current assets as of September 30, 2022, amounted to RMB 859,574.20 million, compared to RMB 654,991.04 million at the end of 2021, reflecting a significant increase[26] - The company's inventory increased to RMB 202,991.58 million as of September 30, 2022, from RMB 125,236.74 million at the end of 2021, indicating a growth in stock levels[26] - The total receivables increased to RMB 168,313.91 million as of September 30, 2022, from RMB 93,540.13 million at the end of 2021, indicating a rise in credit sales[26] - Non-current assets totaled ¥972,857,134.34, a substantial increase from ¥624,540,015.61 year-over-year, representing a growth of approximately 55.7%[31] - Total assets reached ¥1,832,431,331.93, up from ¥1,279,531,053.17, indicating an increase of about 43.1%[31] - Total liabilities increased to ¥351,941,227.22 from ¥234,403,476.40, marking a rise of approximately 50.1%[31] - The company's equity attributable to shareholders rose to ¥1,447,576,635.77, compared to ¥1,042,264,096.63 in the previous year, reflecting an increase of about 38.9%[31] Cash Flow - Cash inflows from operating activities for the first three quarters of 2022 totaled approximately CNY 434.51 million, compared to CNY 263.47 million in the same period of 2021, marking a rise of 64.8%[41] - Cash outflows from operating activities for the first three quarters of 2022 were approximately CNY 386.35 million, compared to CNY 201.33 million in the same period of 2021, an increase of 91.7%[41] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 48.16 million, down from CNY 62.14 million in the same period of 2021, a decrease of 22.5%[41] - Cash inflows from financing activities for the first three quarters of 2022 amounted to CNY 317.45 million, slightly down from CNY 339.29 million in the same period of 2021, a decrease of 6.4%[43] - The net cash flow from financing activities for the first three quarters of 2022 was CNY 270.54 million, compared to CNY 319.76 million in the same period of 2021, reflecting a decrease of 15.4%[43] - The cash and cash equivalents at the end of the third quarter of 2022 were CNY 405.26 million, an increase from CNY 307.32 million at the end of the same period in 2021, representing a growth of 32%[43] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,862, with the top ten shareholders holding a combined 72.67% of the shares[17] - The largest shareholder, Shenzhen Nawei Technology Co., Ltd., held 19.37% of the shares, followed by BIWANG JACK JIANG with 16.03%[17] Future Outlook - The company plans to continue focusing on high-end talent acquisition and enhancing its marketing and application technology teams to drive future growth[11] - The company plans to continue expanding its market presence and investing in new technologies and products to sustain growth in the upcoming quarters[31]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 25%[2]. - The company's operating revenue for the first half of 2022 was CNY 29,383.06 million, representing a 77.41% increase compared to the same period last year[28]. - The net profit attributable to shareholders for the same period was CNY 16,507.09 million, a 153.73% increase year-over-year, including an investment income of CNY 51.54 million from the acquisition of a subsidiary[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 69.73% year-over-year, amounting to CNY 10,265.30 million[28]. - Basic and diluted earnings per share for the period were CNY 0.4125, reflecting a 125.78% increase compared to the same period last year[28]. - The company achieved a revenue of 294 million yuan in the first half of 2022, representing a year-on-year growth of 77.41%[90]. - The net profit attributable to shareholders reached 165 million yuan, an increase of 153.73% compared to the same period last year[90]. - The company reported a net profit of 103 million yuan after deducting non-recurring gains, reflecting a year-on-year growth of 69.73%[90]. Market Expansion and Strategy - User data indicates that the active user base has expanded to 500,000, marking a 30% increase compared to the previous year[2]. - The company has set a revenue guidance for the second half of 2022, projecting an increase of 20% to reach approximately 1.44 billion RMB[2]. - The company is actively pursuing market expansion strategies, targeting a 15% increase in market share within the next year[2]. - The company is planning to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[180]. - A strategic acquisition of a competitor is in progress, which is anticipated to enhance the company's product offerings and increase market competitiveness[181]. Research and Development - Research and development investments have increased by 40%, focusing on innovative solutions in the biopharmaceutical sector[2]. - R&D expenses totaled 39.14 million RMB, a significant increase of 97.79% year-over-year, attributed to team expansion and increased R&D activities[68]. - R&D expenses accounted for 13.32% of total revenue, up from 11.95% in the same period last year, representing an increase of 1.37 percentage points[68]. - The company has developed multiple core technologies in microsphere preparation, structural control, surface modification, and large-scale production, enhancing its competitive edge in the biopharmaceutical and analytical sectors[59]. - The company has filed 7 new invention patents and obtained 5 new authorizations during the reporting period, bringing the total to 126 applications and 45 authorizations[64]. Product Development and Innovation - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of 2022, driven by advancements in technology[2]. - The company launched the UniMab® EXE product, a high-capacity Protein A affinity chromatography medium, which improves antibody processing volume and reduces non-specific adsorption[62]. - The company has developed a new series of chromatographic columns, DNACore, suitable for vaccine and gene therapy drug development and quality control[62]. - The company has developed a range of polymer chromatography fillers, including uniform particle size polymer microspheres with strong alkali resistance, primarily used for large-scale separation and purification of organic small molecules, natural products, peptides, antibiotics, insulin, and nucleotides[49]. Acquisitions and Investments - The company has completed a strategic acquisition of a competitor, which is anticipated to enhance its product offerings and increase overall market competitiveness[2]. - The company completed acquisitions of three companies, including Infini, RILAS, and Saipor Instruments, contributing to an investment income of 51.54 million yuan from the fair value measurement of Saipor Instruments[90]. - The company acquired Saipuri Instruments to extend its product line into purification chromatography systems, enhancing its market position in domestic purification equipment[91]. - The acquisition of RILAS, a Boston-based R&D outsourcing company, aims to expand the company's biomolecule separation and purification services in the North American market[91]. Financial Integrity and Governance - The board has confirmed that there are no non-operational fund usages by controlling shareholders, ensuring financial integrity[2]. - The company has implemented a restricted stock incentive plan, granting shares to 136 employees, which represents 24.91% of the total workforce at the time of the grant, to strengthen ties with core teams[100]. - The company guarantees to provide fair and reasonable pricing for any transactions involving the sale of assets or business related to its subsidiaries, based on normal commercial transaction prices with independent third parties[185]. Environmental Responsibility - The company has established wastewater, waste gas, and solid waste pollution prevention facilities during the initial phase of production project construction[155]. - The company strictly adhered to regulations for hazardous waste storage and disposal, regularly entrusting qualified third parties for compliant disposal[158]. - The company has implemented an emergency response plan for environmental incidents, which has been filed with local environmental authorities[159]. - The company invested approximately RMB 3.8 million in organic solvent recovery facilities at its production bases in Suzhou Industrial Park and Changshu New Materials Industrial Park to reduce carbon emissions[168]. Risks and Challenges - The management has identified potential risks related to supply chain disruptions, which could impact future performance[2]. - The company faces risks related to the potential failure of new product development and the inability to commercialize innovations, which could adversely affect revenue growth and profitability[101]. - The company is exposed to risks of intellectual property theft or infringement, which could undermine its competitive edge in the chromatography media industry[102]. - The company is at risk of supply chain disruptions due to reliance on single suppliers for key raw materials, which could impact production schedules and costs[106].

Financial Performance - The company's revenue for 2021 reached RMB 44,634.68 million, representing a 117.74% increase compared to RMB 20,499.29 million in 2020 [28]. - Net profit attributable to shareholders for 2021 was RMB 18,808.97 million, up 158.75% from RMB 7,269.28 million in 2020 [28]. - The net profit after deducting non-recurring gains and losses was RMB 17,215.87 million, reflecting a 172.09% increase from RMB 6,327.29 million in 2020 [28]. - The net cash flow from operating activities for 2021 was RMB 15,756.39 million, an increase of 118.21% compared to RMB 7,220.84 million in 2020 [28]. - The total assets at the end of 2021 amounted to RMB 127,953.11 million, a 99.97% increase from RMB 63,984.80 million at the end of 2020 [28]. - The net assets attributable to shareholders reached RMB 104,226.41 million, up 94.77% from RMB 53,512.28 million at the end of 2020 [28]. - Basic earnings per share for 2021 were RMB 0.4974, a 143.70% increase from RMB 0.2041 in 2020 [28]. - The weighted average return on equity for 2021 was 23.84%, an increase of 9.17 percentage points from 14.67% in 2020 [28]. Dividend and Capital Management - The proposed cash dividend for the 2021 fiscal year is CNY 0.71 per 10 shares, totaling CNY 28,410,362.31, which represents 15.10% of the net profit attributable to shareholders [7]. - The company does not plan to increase capital reserves or issue bonus shares [7]. - The audit report issued by Rongcheng Accounting Firm is a standard unqualified opinion [6]. Corporate Governance and Compliance - The board of directors and supervisory board members have confirmed the authenticity and completeness of the annual report [4]. - The company has no non-operating fund occupation by controlling shareholders or related parties [9]. - The company has no violations of decision-making procedures for external guarantees [11]. - The company has not disclosed any special arrangements for corporate governance [8]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a substantive commitment to investors [8]. Market and Product Development - The company is focused on expanding its market presence and enhancing its product offerings in the IVD and LCD sectors [22]. - The company plans to continue investing in new product development and technology advancements to drive future growth [22]. - The company's operating revenue for the reporting period increased by 117.74% year-on-year, reaching 446.35 million RMB, driven by the high prosperity of the Chinese biopharmaceutical industry and over a decade of accumulation in drug separation and purification [39]. - Revenue from the biopharmaceutical sector reached 390.24 million RMB, a 134.17% increase year-on-year, accounting for 87.43% of total revenue [40]. - The company developed new products including high-performance reverse-phase silica gel chromatography fillers and mixed-mode ion exchange media, meeting market demands for high standards and efficiency [41]. Research and Development - The company achieved a 98.65% year-on-year increase in R&D expenses, totaling 66.1 million yuan, due to the expansion of the R&D team and increased investment in research activities [84]. - The total R&D expenditure accounted for 14.81% of operating revenue, a decrease of 1.42 percentage points compared to the previous year [83]. - The company has filed 16 new invention patents and received 8 new authorizations during the reporting period, contributing to a cumulative total of 97 applications and 30 authorizations [82]. - The company has developed a comprehensive range of chromatography media, including silica gel and polymer-based materials, to meet diverse customer needs in small and large molecule separation and purification [99]. Risks and Challenges - The company faces risks related to the potential theft of proprietary technologies, which could undermine its competitive advantage in the chromatography media market [107]. - The company is exposed to risks from reliance on single suppliers for raw materials, which could impact production and sales if supply issues arise [109]. - Increased competition from multinational companies and domestic peers in the chromatography media market poses a challenge to the company's market position and growth objectives [112]. Strategic Initiatives - The company plans to enhance its sales team and application technology to increase coverage and service depth for target customers [113]. - The company is closely monitoring industry policies and adjusting its strategies to mitigate risks associated with regulatory changes [120]. - The company aims to provide customized chromatographic materials and solutions during the early R&D stages of biopharmaceutical products, enhancing customer engagement [63]. Management and Remuneration - The total pre-tax remuneration for the chairman and general manager, Jiang Biwang, was CNY 250.54 million for the reporting period [181]. - The total pre-tax remuneration for the financial director and board secretary, Zhao Shun, was CNY 241.74 million for the reporting period [181]. - The total pre-tax remuneration for the deputy general manager and core technical personnel, Chen Rongji, was CNY 246.75 million for the reporting period [181].

Financial Performance - The company's revenue for Q3 2021 reached ¥11,654.38 million, representing a year-on-year increase of 135.17%[7] - Net profit attributable to shareholders for Q3 2021 was ¥5,020.56 million, a significant increase of 220.51% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥4,901.56 million, up 242.70% year-on-year[7] - Total operating revenue for the first three quarters of 2021 reached ¥282,163,223.04, a significant increase from ¥127,812,729.29 in the same period of 2020, representing a growth of approximately 120%[32] - Net profit for the third quarter of 2021 was ¥115,212,551.81, compared to ¥38,832,641.71 in the third quarter of 2020, indicating an increase of about 196%[35] - The company's total comprehensive income for the third quarter of 2021 was ¥115,172,885.13, compared to ¥38,774,704.91 in the same quarter of 2020, representing an increase of approximately 196%[36] Assets and Equity - The total assets at the end of Q3 2021 amounted to ¥111,696.58 million, reflecting a growth of 74.57% from the end of the previous year[16] - The equity attributable to shareholders at the end of Q3 2021 was ¥96,678.99 million, an increase of 80.67% compared to the end of last year[16] - The total assets of the company reached 1,116,965,834.30 RMB, compared to 639,847,972.40 RMB at the end of 2020, marking an increase of around 74.5%[24] - The total equity attributable to shareholders reached ¥966,789,866.62, up from ¥535,122,797.50, marking an increase of around 81%[32] Earnings Per Share - The basic earnings per share for Q3 2021 was ¥0.1255, representing a growth of 185.26% year-on-year[10] - The diluted earnings per share for Q3 2021 was also ¥0.1255, with no dilution factors present[10] - The company reported a basic earnings per share of ¥0.2292 for the third quarter of 2021, compared to ¥0.1109 in the same quarter of 2020, reflecting an increase of approximately 106%[36] Cash Flow - The cash flow from operating activities for the first three quarters of 2021 was ¥6,214.05 million, an increase of 43.81% year-on-year[10] - Cash flow from operating activities for the first three quarters of 2021 was ¥246,954,080.29, significantly higher than ¥122,484,345.84 in the same period of 2020, representing an increase of about 102%[38] - Net cash flow from operating activities amounted to ¥62,140,549.39, an increase from ¥43,209,333.42 in the previous period, reflecting a strong operational performance[42] - The company's cash and cash equivalents amounted to 307,649,287.97 RMB, up from 248,655,300.87 RMB year-over-year, indicating a growth of about 23.6%[24] - The company's cash and cash equivalents at the end of the period stood at ¥307,324,252.33, up from ¥165,293,836.47, reflecting a strong liquidity position[44] Liabilities - The total liabilities increased to ¥146,637,593.19 from ¥103,157,354.61 year-over-year, reflecting a growth of approximately 42%[32] - The total non-current liabilities amounted to ¥57,270,048.41, up from ¥39,685,204.21, indicating an increase of about 44%[32] Research and Development - Research and development expenses for Q3 2021 totaled ¥1,559.51 million, marking a year-on-year increase of 74.28%[16] - Research and development expenses for the first three quarters of 2021 were ¥35,386,011.09, compared to ¥23,548,262.86 in the same period of 2020, showing an increase of approximately 50%[32] Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,233[17] - Shenzhen Nanwei Technology Co., Ltd. holds 78,096,992 shares, accounting for 19.52% of total shares[17] - The top ten shareholders do not participate in margin trading or securities lending activities[23] Investment Activities - Total cash inflow from investment activities was ¥60,600,608.22, significantly higher than the previous period's ¥153.00, indicating active investment management[42] - Cash outflow from investment activities reached ¥323,128,683.57, compared to ¥107,952,106.87 in the prior period, resulting in a net cash flow from investment activities of -¥262,528,075.35[42] Operational Costs - Total cash outflow from operating activities was ¥201,333,014.55, up from ¥101,717,633.36, reflecting increased operational costs[42] - Payments to employees increased to ¥70,450,864.21 from ¥44,249,440.78, indicating a focus on workforce investment[42] Other Information - The company has seen significant growth in sales of chromatography media and related products, driven by the rapid development of China's biopharmaceutical industry[14] - The company has no significant new product or technology developments reported in the current quarter[24] - The company received tax refunds amounting to ¥1,426,538.49, contributing positively to cash flow from operating activities[42]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 25%[12] - The company has set a revenue guidance of RMB 250 million for the full year 2021, which reflects a growth target of 30% year-on-year[12] - The company achieved a revenue of 165.62 million RMB in the first half of the year, representing a 111.64% increase compared to the same period last year[19] - Net profit attributable to shareholders reached 65.06 million RMB, up 172.79% year-on-year[19] - The net profit after deducting non-recurring gains and losses was 60.48 million RMB, reflecting a 203.80% increase compared to the previous year[19] - The company's total assets increased by 64.48% year-on-year, reaching 1.05 billion RMB[20] - The net assets attributable to shareholders grew by 70.82% year-on-year, totaling 914.10 million RMB[20] - Basic earnings per share rose to 0.1827 RMB, a 172.69% increase from the previous year[20] - The company achieved operating revenue of 165.62 million RMB, a year-on-year increase of 111.64%[87] - Revenue from the biopharmaceutical sector amounted to 138.75 million yuan, accounting for 83.78% of total revenue, with a year-on-year growth of 116.00%[73] Research and Development - The R&D expenditure for the first half of 2021 was RMB 15 million, accounting for 15% of total revenue, aimed at innovation and product enhancement[12] - The company has established partnerships with three leading universities for collaborative research projects[12] - The company focuses on high-performance nano-microsphere materials for applications in biomedicine, flat panel displays, and in vitro diagnostics[26] - The company has developed a robust R&D model, focusing on specific projects with a full-cycle management approach, leading to advancements in microsphere synthesis and functionalization technologies[36] - The company has accumulated multiple core technologies in microsphere precision preparation and large-scale production over more than ten years of R&D[47] - The company achieved a 35.55% increase in R&D expenses, totaling CNY 19.79 million, compared to CNY 14.60 million in the previous period[55] - R&D expenses accounted for 11.95% of total revenue, a decrease of 6.71 percentage points from 18.66% in the previous period[55] - The company has developed single-dispersed silica gel chromatography fillers with a coefficient of variation (CV) of less than 3%[48] - The company has developed a high-capacity, alkali-resistant Protein A affinity chromatography medium, suitable for industrial-scale production[51] - The company has developed a high-performance silica gel chromatography filler, currently in the customer verification stage, with an investment of RMB 387.68 million and a cumulative investment of RMB 1,476.29 million[59] Market Strategy and Expansion - User data indicates a growth in active users by 15% compared to the previous period, reaching 1.5 million active users[12] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[12] - A strategic acquisition of a local competitor is under consideration to enhance product offerings and market reach[12] - The company aims to become a leading global brand in microsphere technology, emphasizing innovation and cross-field collaboration[27] - The company is positioned to leverage its technological advantages in the growing biopharmaceutical separation and purification market[38] - The company is expanding its sales team and enhancing customer service to better meet the needs of pharmaceutical clients, which may lead to increased market share[45] Environmental Compliance and Sustainability - The management emphasizes a commitment to sustainability, with plans to reduce carbon emissions by 20% by 2025[12] - The company and its subsidiary, Changshu Nami, are classified as key pollutant discharge units, adhering to national and local pollution discharge standards[109] - The company has implemented measures for the safe disposal of solid waste and hazardous waste through qualified units[109] - The company maintains compliance with environmental regulations, with all pollutant discharge indicators meeting the required standards[109] - The company invested approximately RMB 3.8 million in the construction of organic solvent recovery devices, achieving the recovery and reuse of about 700 tons of organic solvents such as ethanol, propanol, and xylene during the reporting period[125] - The company’s environmental management system has been certified according to ISO 14001:2015, with a recommendation to maintain certification following a third-party audit[124] Risks and Challenges - The company has identified potential risks including supply chain disruptions and regulatory changes, with mitigation strategies outlined in the report[4] - The company is facing risks from intensified market competition and potential policy changes in the biopharmaceutical industry[80][84] Shareholder and Corporate Governance - The company will not use its controlling shareholder status to harm the interests of the company, its subsidiaries, or other shareholders[139] - The company commits to timely and fully disclose any failure to execute its commitments made during the IPO process[141] - The company will avoid related party transactions and ensure they are conducted at fair market prices if necessary[142] - The company will comply with all legal and regulatory requirements regarding share lock-up and reduction commitments[146] - The company will ensure that any related party transactions are conducted legally and fairly, avoiding any harm to the company and its shareholders[144]